Brain-Targeting Delivery of Two Peptidylic Inhibitors for Their Combination Therapy in Transgenic Polyglutamine Disease Mice via Intranasal Administration
Publication in refereed journal


摘要Polyglutamine diseases are a set of progressive neurodegenerative disorders caused by misfolding and aggregation of mutant CAG RNA and polyglutamin protein. To date, there is a lack of effective therapeutics that can counteract the polyglutamine neurotoxicity. Two peptidylic inhibitors, QBP1 and P3, targeting the protein and RNA toxicities, respectively, have been previously demonstrated by us with combinational therapeutic effects on the Drosophila polyglutamine disease model. However, their therapeutic efficacy has never been investigated in vivo in mammals. The current study aims to (a) develop a brain-targeting delivery system for both QBP1 and L1P3V8 (a lipidated variant of P3 with improved stability) and (b) evaluate their therapeutic effects on the R6/2 transgenic mouse model of polyglutamine disease. Compared with intravenous administration, intranasal administration of QBP1 significantly increased its brain-to-plasma ratio. In addition, employment of a chitosan-containing in situ gel for the intranasal administration of QBP1 notably improved its brain concentration for up to 10-fold. Further study on intranasal cotreatment with the optimized formulation of QBP1 and L1P3V8 in mice found no interference on the brain uptake of each other. Subsequent efficacy evaluation of 4-week daily QBP1 (16 mu mol/kg) and L1P3V8 (6 mol/kg) intranasal cotreatment in the R6/2 mice demonstrated a significant improvement on the motor coordination and explorative behavior of the disease mice, together with a full suppression on the RNA- and protein-toxicity markers in their brains. In summary, the current study developed an efficient intranasal cotreatment of the two peptidylic inhibitors, QBP1 and L1P3V8, for their brain targeting, and such a novel therapeutic strategy was found to be effective on a transgenic polyglutamine disease mouse model.
著者Mengbi Yang, Qian Zhang, Qianwen Wang, Kasper K. Sørensen, Josephine T. Boesen, Sum Yi Ma, Knud J. Jensen, Kin Ming Kwan, Jacky Chi Ki Ngo, Ho Yin Edwin Chan, Zhong Zuo
期刊名稱Molecular Pharmaceutics
頁次5781 - 5792
關鍵詞polyglutamine diseases, in situ gel, QBP1, P3, L1P3V8, peptide therapeutics, polyglutamine protein, expanded-CAG RNA

上次更新時間 2020-03-12 於 01:18